Omkostningseffektivitet ved alendonatbehandling af osteoporose i Danmark. En ökonomisk evaluering baseret på Fracture Intervention
Trial-undersögelsen
Engelsk titel: Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial
Läs online
Författare:
Jönsson L
;
Borgström F
;
Zethraeus N
Email: linus.j@healtheconomics.se
Språk: Dan
Antal referenser: 18
Dokumenttyp:
Artikel
UI-nummer: 03111627
Sammanfattning
Introduction: Based on a clinical study, the Fracture Intervention Trial, we assessed the cost-effectiveness of treating elderly women with osteoporosis with the biphosphonate alendronate in a Danish environment. Material and methods: The cost-effectiveness was estimated in a Markov-model. Costs, health effects and risk of fractures were taken from previously published sources. Health effects were measured as Quality Adjusted Life-Years (QALYs) and life-years gained. Results were presented with and without costs of added life years. The cost-effectiveness was investigated for two patient groups. The first group consisted of elderly women with osteoporosis and previous vertebral fractures and the second group consisted of women without prevalent vertebral fractures but a low BMD. Results: The costs per gained QALY were estimated to DKK 13,277 (women with osteoporosis and a previous vertebral fracture) and DKK 150,249 (women with osteoporosis). Discussion: The estimated costs per gained QALY were below suggested threshold values, indicating that treatment with alendronate was cost-effective for both patient groups.